DS
DSP Healthcare Fund Direct Growth
Latest NAV
+15.61% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
0.73%
AUM
₹3,835 Cr
Min SIP
₹100
Min lump sum
₹100
1Y
+15.61%
3Y (ann.)
+20.70%
5Y (ann.)
+15.23%
Launched
Nov 2018
Where the NAV sits & how risky it is
₹49.80
52-week range
at 84%
₹49.80
Low 23 Mar 2026₹39.92
High 31 Aug 2026₹51.69
Risk level
Very High
Low
Very high
NAV history
03 Dec 2018
Since inception
01 Oct 2026
Returns by period
1W
-3.06%
1M
-3.45%
3M
+3.21%
6M
+23.07%
1Y
+15.61%
3Y
+20.70%
5Y
+15.23%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹100
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 92.78%
Funds & ETFs 0.88% Cash & other 6.59%
Sector split
Country split
Top 5 hold 38.2%
Top 10 hold 63.6%
30 equity holdings
Equity holdings
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
8.35%
|
+4.97% |
| 2 | IPCA Laboratories
INE571A01038 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
7.81%
|
+14.89% |
| 3 | Cipla
INE059A01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
7.68%
|
-8.03% |
| 4 | Illumina Inc |
Healthcare Diagnostics & Research |
United States |
7.53%
|
+23.88% |
| 5 | Sai Life Sciences
INE570L01029 |
Healthcare Diagnostics & Research |
India |
6.86%
|
+30.79% |
| 6 | Globus Medical Inc Class A |
Healthcare Medical Devices |
United States |
6.34%
|
-7.39% |
| 7 | Gland Pharma
INE068V01023 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.26%
|
+33.94% |
| 8 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
4.81%
|
+20.67% |
| 9 | Cohance Lifesciences
INE03QK01018 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.15%
|
-18.56% |
| 10 | Laurus Labs
INE947Q01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.76%
|
+25.17% |
About this scheme
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities.
Fund manager(s): Chirag Dagli
Exit load: Exit load of 0.50% if redeemed within 1 month.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
30 Nov 2018
Lump-sum min
₹100
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 105.9 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 17.8 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 15.0 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 15.0 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 13.6 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 13.5 pts ahead of this fund